CIK 0000818686 · Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- Phone
- 972 (3) 914-8213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,923,078
- in 11 filings, $11.2M under 10b5-1 plans
Net −$33,923,078. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-04 | Francis Richard D President and CEO | Sale 10b5-1 | −23,393 | $32.46 | $759K | 1,148,212 |
| 2026-03-04 | Francis Richard D President and CEO | Option exercise · Restricted Share Units 10b5-1 | −50,223 | 100,446 | ||
| 2026-03-04 | Francis Richard D President and CEO | Grant or award · Restricted Share Units 10b5-1 | +136,736 | 136,736 | ||
| 2026-03-04 | Daniell Richard EVP, Europe Commercial | Option exercise 10b5-1 | +33,512 | 156,639 | ||
| 2026-03-04 | Daniell Richard EVP, Europe Commercial | Sale 10b5-1 | −33,512 | $32.46 | $1.1M | 123,127 |
| 2026-03-04 | Daniell Richard EVP, Europe Commercial | Option exercise 10b5-1 | +20,461 | 143,588 | ||
| 2026-03-04 | Daniell Richard EVP, Europe Commercial | Sale 10b5-1 | −20,461 | $32.46 | $664K | 123,127 |
| 2026-03-04 | Daniell Richard EVP, Europe Commercial | Sale 10b5-1 | −37,372 | $32.95 | $1.2M | 85,755 |
| 2026-03-04 | Daniell Richard EVP, Europe Commercial | Option exercise · Restricted Share Units 10b5-1 | −33,512 | 0 | ||
| 2026-03-04 | Daniell Richard EVP, Europe Commercial | Option exercise · Restricted Share Units 10b5-1 | −20,461 | 40,923 | ||
| 2026-03-04 | Daniell Richard EVP, Europe Commercial | Grant or award · Restricted Share Units 10b5-1 | +33,424 | 33,424 | ||
| 2026-03-04 | Jover Placid See "Remarks" | Grant or award · Restricted Share Units | +37,982 | 37,982 | ||
| 2026-03-04 | Shields Matthew EVP, Global Operations | Grant or award · Restricted Share Units | +33,424 | 33,424 | ||
| 2026-03-04 | Sabag Mark See "Remarks" | Option exercise | +33,512 | 252,718 | ||
| 2026-03-04 | Sabag Mark See "Remarks" | Option exercise | +18,601 | 271,319 | ||
| 2026-03-04 | Sabag Mark See "Remarks" | Option exercise · Restricted Share Units | −33,512 | 0 | ||
| 2026-03-04 | Sabag Mark See "Remarks" | Option exercise · Restricted Share Units | −18,601 | 37,202 | ||
| 2026-03-04 | Sabag Mark See "Remarks" | Grant or award · Restricted Share Units | +30,385 | 30,385 | ||
| 2026-03-04 | Lippman Evan EVP, Business Development | Grant or award · Restricted Share Units | +27,347 | 27,347 | ||
| 2026-03-04 | Hughes Eric A See "Remarks" | Option exercise 10b5-1 | +23,251 | 108,867 |
Page 7 of 64 · 1,279 trades